ERBB2 and breast cancer: Similarly, the EGF103009 trial confirmed that patients with HER2-positive inflammatory BC benefit from lapatinib but no clinical activity was observed in patients with EGFR-positive HER2-negative tumors, suggesting that lapatinib exhibits antitumor effects through HER2 receptor rather than EGFR.